Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib + panitumumab versus investigator's choice in previously treated KRAS p.G12C metastatic colorectal cancer
2021-004008-16Phase 3Active
- Sponsor
- Amgen
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sotorasib and panitumumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Amgen. Primary endpoint: Progression-free survival. Started Nov 2021; status: active.
02
Drugs
sotorasibpanitumumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2021-004008-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004008-16.